lobeglitazone + warfarin

**Lobeglitazone + warfarin** is a fixed-dose combination consisting of lobeglitazone, a thiazolidinedione-class antidiabetic drug and peroxisome proliferator-activated receptor gamma (PPAR-γ) agonist used for type 2 diabetes mellitus, and warfarin, a vitamin K antagonist anticoagulant used to prevent and treat thromboembolic disorders[1][3]. Lobeglitazone increases insulin sensitivity by activating PPAR-γ, promoting glucose uptake in adipocytes and muscle, while warfarin acts by inhibiting vitamin K epoxide reductase complex (VKORC1), thereby impairing hepatic synthesis of vitamin K-dependent clotting factors (II, VII, IX, X)[1]. The combination is utilized when patients with type 2 diabetes require anticoagulation, though these drugs are typically prescribed independently and not as a uniquely branded combination. Drug-drug interaction trials confirmed that co-administration does not alter the pharmacokinetics or pharmacodynamics of either drug, so dosage adjustments are generally not needed[1][5].

Other names

thiazolidinedione + coumarin anticoagulantlobeglitazone and warfarin